Liver Neoplasms (Liver Cancer)

Tumors or cancer of the LIVER.
Also Known As:
Liver Cancer; Cancer of the Liver; Hepatic Neoplasms; Neoplasms, Hepatic; Neoplasms, Liver; Cancer, Hepatic; Cancer, Liver; Cancers, Hepatic; Cancers, Liver; Hepatic Cancers; Hepatic Neoplasm; Liver Cancers; Liver Neoplasm; Neoplasm, Hepatic; Neoplasm, Liver; Cancer of Liver; Hepatic Cancer
Networked: 6078 relevant articles (228 outcomes, 848 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Hepatocellular Carcinoma (Hepatoma)
3. Neoplasm Metastasis (Metastasis)
4. Fibrosis (Cirrhosis)
5. Infection


1. Calvisi, Diego F: 23 articles (03/2015 - 05/2003)
2. Thorgeirsson, Snorri S: 21 articles (10/2015 - 02/2003)
3. Lu, Shelly C: 19 articles (11/2015 - 04/2005)
4. Kudo, Masatoshi: 18 articles (11/2015 - 01/2003)
5. Groopman, John D: 17 articles (01/2015 - 08/2002)
6. Liu, Jie: 15 articles (10/2015 - 06/2007)
7. Li, Li: 15 articles (08/2015 - 07/2002)
8. Llovet, Josep M: 15 articles (04/2015 - 03/2005)
9. Wang, Jiayi: 15 articles (01/2015 - 03/2010)
10. Mato, José M: 14 articles (11/2015 - 04/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Neoplasms:
1. sorafenib (BAY 43-9006)FDA Link
2. Doxorubicin (Adriamycin)FDA LinkGeneric
3. Ethiodized Oil (Ethiodol)FDA Link
03/01/2015 - "The newly synthesized (188)Re-HDD/lipiodol showed improved radiolabeling yield and biodistribution results compared to (188)Re-HTDD/lipiodol, and may therefore be more suitable for liver cancer therapy."
07/01/2010 - "Reported CR ratio of definitely hypervascular HCC are around 30-60% by superselective TACE with Lipiodol for hypervascular HCC less than 5 cm. According to a nationwide survey by the Liver Cancer Study Group of Japan (LCSGJ), overall 5-year survival rate was 26% in patients with HCCs not indicated for surgery or RFA (PEI), mainly treated by segmental or subsegmental TACE using Lipiodol. "
03/01/2008 - "The Nuclear Medicine Section of IAEA's Division of Human Health initiated the first Doctoral CRP of IAEA in the year 2000, entitled, "Management of Liver Cancer Using Radionuclide Methods with Special Emphasis on Trans-Arterial Radio-conjugate Therapy and Internal Dosimetry." Since then, the CRP has accomplished several milestones, including development of a new therapeutic radiopharmaceutical ((188)Re lipiodol) and successfully carrying out Phase I and Phase II clinical trials on patients using the new therapeutic radiopharmaceutical."
01/01/2007 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. "
03/01/2015 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HTDD) has been successfully developed for liver cancer therapy; however, its preparation requires a multi-step synthesis and it is characterized by a low labeling yield. "
4. Small Interfering RNA (siRNA)IBA
5. AflatoxinsIBA
6. alpha-Fetoproteins (AFP)IBA
7. Ethanol (Ethyl Alcohol)IBA
8. AntigensIBA
9. Biological Markers (Surrogate Marker)IBA
10. Liposomes (Liposome)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Hepatectomy
3. Liver Transplantation
4. Immunotherapy
5. Radiotherapy